Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release

Drug Design, Development and Therapy

Volumn 5, Issue , 2011, Pages 455-463

  Benedek, Irma H ^a   Jobes, Janet ^a   Xiang, Qinfang ^a   Fiske, William D ^a  

^a ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Abuse deterrent; Bioequivalence; Opioid; Oxymorphone; Pharmacokinetics; Substance abuse

Indexed keywords

6 HYDROXYOXYMORPHONE; EN 3288; NALTREXONE; OPIATE AGONIST; OXYMORPHONE; TIMERX; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOTRANSFORMATION; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DEMOGRAPHY; FEMALE; HARDNESS; HUMANS; HYDROXYLATION; MALE; MIDDLE AGED; OXYMORPHONE; SAFETY; SOLUBILITY; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84859152253     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S24372     Document Type: Article

References (16)

1. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11(2 Suppl): S63-S88.
2. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5-13.
3. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2): 113-130.
4. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11(2 Suppl):S5-S62.
5. OPANA ER (oxymorphone hydrochloride extended-release tablets). Full Prescribing Information. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2008.
6. Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004;24(4):468-476.
7. Fiske W, Jobes J, Xiang Q, Chang S, Benedek I. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets J Pain. 2011. In press.
8. US Department of Health and Human Services. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Available at: http://www.fda.gov/downloads/Durgs/Guidancecomplianceregulatoryinformation/guidances/ucm070124.pdf. Accessed October 29, 2010.
9. Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of Opana ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175-184.
10. Katz N, Rauck R, Ahdieh H, et al. A 12-week randomized placebocontrolled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117-128.
11. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin. 2004;20(6):911-918.
12. Slatkin NE, Rhiner MI, Gould EM, Ma T, Ahdieh H. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. J Opioid Manag. 2010;6(3):181-191.
13. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther. 2006;28(3):352-364.
14. McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther. 2005;12(2):106-112.
15. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7): 613-624.
16. Cone EJ, Caplan YH. Urine toxicology testing in chronic pain management. Postgrad Med. 2009;121(4):91-102.